ArticleOncology research2025
ETS Family Transcription Factors in Gastric Cancer and the Role of ELF3 in the Core Metaplasia Transcription Factor Network.
Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: E26 transformation-specific (ETS) family transcription factors have confirmed roles in several types of cancers. This study aimed to clarify the role of ETS family transcription factor alterations in gastric cancers. Methods: This study examines molecular alterations of ETS transcription factors in gastric adenocarcinomas based on an analysis of publicly available cohorts from the Protein Atlas and the Cancer Genome Atlas. The expression and relationships of members of the ETS transcription factor family with other important factors in the process of gastric carcinogenesis were evaluated using the same resources. Results: mRNA expression levels of ETS family members in gastric carcinoma tissues were variable, with ELF3, ETS2, EHF, ERF, and ELF1 being the family members with the highest expression. Mutations in individual transcription factors of the ETS family were rare in gastric cancers. The family member ELF3 was well expressed in the mRNA level in a subset of gastric cancers (n = 91), and its expression correlated with the expression of other transcription factors involved in gastric cancer pathogenesis, including HNF4A, HNF1A, CDX2, GATA4, GATA6, and EHF. Cancers with high co-expression of ELF3 and HNF4A were frequently chromosomally instability (CIN), intestinal-type adenocarcinomas, and harbored Conclusion: Expression of E74 like ETS transcription factor 3 (ELF3), an ETS transcription family member, correlates with expression of other key factors in gastric cancer and confers specific characteristics that may become exploited in targeted therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.